Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)

Trial Details

NCT ID
NCT05477589
Phase
PHASE3
Sponsor
Vastra Gotaland Region
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • busulfan, cyclophosphamide and melphalan, BuCyMel
  • clofarabine, fludarabine and busulfan, CloFluBu
Locations (sample)
  • Brussels, Belgium|50.85045,4.34878
  • Brussels, Belgium|50.85045,4.34878
  • Ghent, Belgium|51.05,3.71667
  • Leuven, Belgium|50.87959,4.70093
  • Liège, Belgium|50.63373,5.56749

Key Eligibility Criteria

  • Age ≤18 years at time of initial AML, age ≤ 21 years at transplantation.
  • HCT is performed in a study participating center
  • All women of childbearing potential who have to have a negative pregnancy test within 2 weeks prior to the start of treatment.
  • Signed informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →